background
multipathogen
revers
transcript
realtim
pcr
rtqpcr
platform
proven
use
surveil
acut
respiratori
ill
ari
studi
respiratori
outbreak
unknown
etiolog
taqman
array
card
tac
life
technolog
tm
simultan
test
clinic
specimen
individu
pathogen
depend
arrang
control
use
duplic
well
array
singleplex
rtqpcr
singl
assay
card
use
minim
amount
clinic
specimen
previou
studi
describ
develop
tac
detect
respiratori
viral
bacteri
pathogen
assay
evalu
wellcharacter
analyt
materi
limit
collect
human
clinic
specimen
object
wish
compar
tac
assay
perform
standard
individu
rtqpcr
assay
respiratori
viral
detect
focus
virus
adenoviru
human
metapneumoviru
human
parainfluenza
virus
influenza
virus
b
respiratori
syncyti
viru
rhinoviru
larger
collect
human
specimen
studi
design
use
specimen
children
ari
enrol
systemat
populationbas
ari
surveil
studi
new
vaccin
surveil
network
nvsn
result
compar
standard
individu
rtqpcr
assay
sensit
tac
target
virus
rang
adenoviru
human
parainfluenza
respect
virus
assay
specif
coeffici
variat
viru
control
rang
conclus
tac
assay
prove
use
multipathogen
studi
rapid
outbreak
respons
number
multipathogen
molecular
platform
simultan
detect
wide
array
pathogen
develop
rapidli
determin
caus
respiratori
diseas
outbreak
unknown
etiolog
facilit
surveil
expand
etiolog
acut
respiratori
infect
ari
one
system
taqman
array
card
tac
life
technolog
tm
carlsbad
ca
allow
simultan
singleplex
revers
transcript
realtim
pcr
rtqpcr
perform
microfluid
card
format
cardbas
system
use
success
studi
brain
endotheli
cell
gene
express
mirna
express
profil
biolog
agent
detect
flexibl
card
format
allow
simultan
test
clinic
specimen
presenc
target
pathogen
along
appropri
posit
neg
assay
control
kodani
et
al
report
first
applic
tac
formerli
tlda
taqman
low
densiti
array
infecti
diseas
diagnost
use
card
design
simultan
detect
differ
respiratori
viral
bacteri
pathogen
advantag
tac
system
includ
simpl
easi
oper
reproduc
simultan
analys
multipl
pathogen
use
small
sampl
volum
level
detect
gener
within
one
tenfold
dilut
individu
rtqpcr
assay
lower
risk
amplicon
contamin
system
entir
close
unlik
multiplex
platform
abil
modifi
replac
individu
pathogen
assay
primerprob
without
requir
reoptim
valid
entir
panel
howev
sever
gap
knowledg
remain
complet
studi
first
frozen
archiv
clinic
specimen
util
collect
variou
studi
locat
year
period
prevent
evalu
standard
method
establish
epidemiolog
associ
second
total
nucleic
acid
tna
extract
dilut
order
provid
suffici
volum
perform
comparison
tac
individu
rtqpcr
assay
factor
along
frozen
storag
may
contribut
decreas
sensit
tac
assay
rel
individu
rtqpcr
assay
third
order
achiev
consensu
amplif
condit
deploy
individu
rtqpcr
tac
assay
higher
probeann
temperatur
c
chosen
requir
optim
bacteri
assay
specif
potenti
loss
sensit
viral
assay
design
run
c
loss
viral
sensit
might
bias
result
toward
increas
concord
among
fals
neg
individu
rtqpcr
assay
tac
assay
result
overestim
tac
sensit
virus
wish
extend
work
kodani
et
al
appli
tac
larger
field
studi
systemat
collect
specimen
children
wellcharacter
recent
fever
acut
respiratori
infect
ari
use
specimen
children
enrol
new
vaccin
surveil
network
nvsn
conduct
systemat
populationbas
surveil
ari
standard
protocol
collect
epidemiolog
microbiolog
data
sensit
specif
viral
detect
tac
assay
format
determin
target
respiratori
virus
standard
individu
rtqpcr
assay
place
use
ident
primer
probe
set
tac
individu
rtqpcr
tabl
individu
rtqpcr
assay
optim
viral
detect
use
anneal
temperatur
c
maxim
sensit
gold
standard
overal
studi
design
nvsn
conduct
surveil
ari
among
children
us
counti
includ
citi
rochest
new
york
nashvil
tennesse
cincinnati
ohio
overal
surveil
design
laboratori
methodolog
describ
previous
sinc
distribut
virus
rel
similar
across
counti
resourc
limit
util
specimen
rochest
monro
counti
new
york
nvsn
site
studi
cohort
tac
individu
rtqpcr
assay
result
compar
cohort
compris
children
fever
acut
respiratori
infect
hospit
children
year
age
enrol
octob
septemb
children
year
age
seen
emerg
depart
ambulatori
clinic
enrol
octob
june
part
standard
nvsn
protocol
inform
consent
parentsguardian
detail
epidemiolog
data
parent
tabl
primer
probe
use
studi
individu
rtqpcr
tac
assay
primerprob
sequenc
biosearch
technolog
inc
novato
ca
except
probe
intern
quench
locat
modifi
residu
termin
spacer
biosearch
technolog
inc
prevent
probe
extens
taq
polymeras
b
subsequ
studi
primer
redesign
improv
assay
perform
c
anneal
temperatur
f
aca
agt
tgt
caa
ygt
ctt
aat
tcr
tat
r
tcg
gca
cct
aag
tar
tti
tga
gtt
c
rhinoviru
rtqpcr
assay
may
crossreact
enteroviru
strain
present
high
viral
load
interview
provid
immun
data
midturbin
nasal
throat
swab
specimen
steril
nonflock
polyestertip
applic
puritan
medic
guilford
collect
enrol
children
swab
combin
univers
transport
medium
diagnost
hybrid
athen
oh
refriger
ad
lysi
buffer
qiagen
lysi
buffer
avl
qiagen
inc
valencia
ca
within
h
aliquot
origin
sampl
sampl
lysi
buffer
store
c
lysi
buffer
serv
prevent
viral
particl
degrad
sampl
freez
inactiv
rnase
present
sampl
stabil
intact
viral
rna
futur
analysi
laboratori
test
work
perform
univers
rochest
medic
center
tna
extract
l
specimen
aliquot
lysi
buffer
final
eluat
volum
l
use
qiaamp
viral
rna
mini
kit
qiagen
qiacub
robot
qiagen
minim
freezethaw
three
tna
aliquot
extract
clinic
specimen
prepar
store
c
use
individu
rtqpcr
assay
virus
adenoviru
human
metapneumoviru
hmpv
human
parainfluenza
virus
influenza
virus
b
respiratori
syncyti
viru
rsv
rhinoviru
human
rnase
p
rnp
refer
gene
control
use
comparison
tac
tabl
individu
rtqpcr
assay
except
influenza
virus
b
perform
appli
biosystem
realtim
pcr
system
life
technolog
tm
use
agpathid
tm
onestep
rtpcr
life
technolog
tm
kit
previous
describ
kodani
et
al
modifi
use
standard
optim
thermocycl
condit
viral
assay
c
min
c
min
cycl
c
c
individu
rtqpcr
perform
biorad
myiq
tm
rtqpcr
thermal
cycler
biorad
laboratori
hercul
ca
use
condit
note
influenza
virus
b
assay
perform
biorad
myiq
tm
rtqpcr
thermal
cycler
use
superscript
iii
platinum
onestep
rtpcr
chemistri
life
technolog
tm
follow
thermocycl
condit
c
min
c
min
cycl
c
c
cycl
threshold
c
valu
assign
specimen
exhibit
exponenti
fluoresc
curv
accept
control
result
ie
neg
result
notempl
control
posit
result
rnp
refer
gene
control
studi
c
valu
consid
posit
test
result
panel
tac
assay
use
studi
modifi
kodani
et
al
includ
viral
bacteri
respiratori
pathogen
adenoviru
hmpv
hpiv
influenza
virus
b
c
rsv
rhinoviru
human
coronavirus
enteroviru
bordetella
pertussi
chlamydophila
pneumonia
haemophilu
influenza
legionella
pneumophila
mycoplasma
pneumonia
streptococcu
pneumonia
pyogen
resourc
limit
individu
rtqpcr
assay
could
perform
virus
tac
assay
result
present
herein
therefor
limit
viral
pathogen
tabl
tac
card
creat
handl
fashion
kodani
et
al
studi
ident
primer
probe
use
tabl
except
work
ad
new
tac
card
panel
individu
rtqpcr
assay
addit
rhinoviru
primer
probe
slightli
modifi
tac
rtqpcr
tabl
tac
card
also
contain
primer
probe
influenza
c
coronaviru
type
note
relev
current
report
synthet
oligonucleotid
primerprob
use
individu
rtqpcr
assay
tac
design
center
diseas
control
prevent
cdc
synthes
biosearch
technolog
inc
novato
ca
primerprob
select
viru
assay
spot
duplic
card
life
tchnolog
tm
qualiti
control
assay
perform
compani
cdc
viral
assay
two
lot
tac
card
use
studi
qualifi
use
use
standard
refer
control
reagent
addit
viral
primersprob
proprietari
intern
posit
control
ipc
assay
spot
duplic
oligonucleotid
templat
life
technolog
tm
monitor
specimen
inhibitor
rtqpcr
rnp
assay
note
spot
singli
monitor
specimen
qualiti
assay
human
glyceraldehyd
dehydrogenas
also
includ
card
manufactur
qualiti
control
card
product
lot
result
assay
includ
analysi
card
test
includ
clinic
specimen
notempl
neg
control
reaction
mix
plu
water
monitor
assay
contamin
posit
control
pool
viral
genom
synthet
templat
period
run
prespecifi
interv
includ
begin
midpoint
end
studi
card
monitor
pathogenand
rnpspecif
assay
perform
control
monitor
throughout
studi
ensur
test
valid
specimen
test
l
tna
extract
l
agpathid
tm
onestep
rtpcr
master
mix
load
one
tac
port
card
centrifug
twice
distribut
tnamast
mix
throughout
interconnect
well
per
specimen
contain
prespot
primerprob
card
seal
run
viia
tm
realtim
pcr
system
life
technolog
tm
use
follow
thermocycl
condit
c
min
c
min
cycl
c
follow
c
min
describ
kodani
et
al
assign
c
valu
posit
test
result
indic
individu
rtqpcr
assay
c
valu
present
mean
two
duplic
well
specimen
yield
posit
assay
specimen
discord
posit
neg
duplic
well
c
valu
posit
viral
specimen
tac
posit
valu
assign
sensit
specif
calcul
use
individu
rtqpcr
result
gold
standard
confid
interv
ci
around
point
estim
sensit
calcul
accord
efficientscor
method
correct
continu
use
vassarstat
websit
statist
comput
http
vassarstatsnet
group
data
present
mean
sd
median
rang
interquartil
rang
iqr
note
clinic
specimen
test
individu
rtqpcr
assay
posit
one
respiratori
virus
evalu
specimen
posit
one
viru
total
virus
detect
compar
sensit
tac
assay
individu
target
viru
rtqpcr
assay
shown
tabl
overal
sensit
virus
tac
individu
viru
assay
sensit
rang
tac
assay
influenza
b
hmpv
rsv
exhibit
highest
sensit
rang
wherea
assay
adenoviru
lowest
sensit
respect
gener
c
valu
tac
similar
individu
rtqpcr
assay
tabl
linear
concord
two
system
high
fig
tac
c
valu
tend
slightli
higher
individu
rtqpcr
valu
denot
fig
valu
refer
line
except
influenza
virus
b
tac
result
discord
individu
rtqpcr
assay
result
nearli
alway
higher
rang
individu
rtqpcr
c
valu
c
tac
almost
alway
posit
individu
rtqpcr
c
valu
notabl
except
rhinoviru
assay
fig
studi
note
tac
perform
lag
behind
tac
assay
thirteen
sampl
posit
individu
rtqpcr
avail
test
retest
tac
anneal
temperatur
c
improv
tac
assay
perform
obtain
lower
anneal
temperatur
assay
sensit
increas
comparison
point
estim
sensit
well
number
true
posit
virus
test
defin
posit
individu
rtqpcr
result
work
kodani
et
al
present
work
present
tabl
ci
shown
tabl
result
kodani
et
al
recalcul
method
present
result
instanc
appar
fals
posit
tac
assay
result
rsv
rhinoviru
posit
among
sampl
neg
rtqpcr
overal
tac
specif
throughout
studi
c
valu
posit
control
pool
tightli
distribut
coeffici
variat
cv
rang
target
viru
rnp
gene
control
tabl
c
valu
ipc
also
tightli
distribut
cv
similar
mean
median
valu
whether
respiratori
specimen
tna
extract
water
notempl
control
present
indic
absenc
rtqpcr
inhibitor
studi
specimen
tabl
found
tac
assay
offer
simpl
sensit
reproduc
moder
throughput
system
simultan
detect
multipl
respiratori
pathogen
tac
assay
pathogen
accomplish
l
nucleic
acid
extract
l
reaction
mix
per
patient
sampl
card
setup
run
time
h
exclud
sampl
extract
card
sampl
could
feasibl
run
singl
machin
normal
workday
contrast
complet
individu
rtqpcr
reaction
clinic
sampl
would
requir
l
nucleic
acid
extract
l
reaction
mix
well
much
greater
amount
technician
time
preclud
throughput
even
clinic
specimen
test
pathogen
per
day
addit
advantag
tac
assay
combin
datafil
output
pathogen
test
per
specimen
merg
result
separ
rtqpcr
assay
requir
avoid
pipet
error
multiwel
plate
rtqpcr
assay
autom
setup
tac
array
assay
inde
excel
reproduc
control
maintain
throughout
durat
studi
among
clinic
specimen
test
individu
rtqpcr
tac
assay
target
virus
overal
tac
sensit
specif
respect
kodani
et
al
found
tac
sensit
specif
smaller
test
set
virusposit
specimen
target
virus
includ
analysi
yield
similar
estim
sensit
specif
viru
assay
except
lower
sensit
adenoviru
rhinoviru
tabl
part
discrep
might
explain
fact
kodani
et
al
use
anneal
temperatur
c
individu
rtqpcr
assay
may
decreas
rtqpcr
sensit
thu
make
concord
neg
tac
assay
result
ie
fals
neg
rtqpcr
result
would
increas
concord
fals
neg
tac
result
rais
estim
tac
sensit
adenovirus
rhinovirus
addit
factor
may
greater
strain
variat
adenovirus
rhinovirus
reduc
perform
tac
primersprob
virus
analyz
c
rather
c
abl
pursu
studi
effect
adenoviru
rhinoviru
strain
variat
anneal
temperatur
tac
assay
due
limit
resourc
also
note
decreas
tac
assay
sensit
sinc
one
advantag
close
tac
system
abil
modifi
replac
primerprob
individu
pathogen
without
requir
reoptim
valid
entir
panel
updat
primer
futur
tac
card
improv
assay
sensit
c
tabl
one
major
limit
studi
perform
individu
rtqpcr
analys
sever
viral
bacteri
pathogen
tac
array
therefor
unabl
studi
assay
work
howev
kodani
et
al
found
good
perform
detect
bacteri
pathogen
studi
also
low
number
posit
clinic
specimen
influenza
b
viru
led
wide
confid
interv
around
point
estim
tac
sensit
howev
note
confid
interv
around
estim
viral
sensit
overlap
result
kodani
et
al
nearli
virus
test
tabl
abl
compar
tac
perform
directli
array
technolog
filmarray
respiratori
panel
biofir
diagnost
inc
salt
lake
citi
ut
luminex
xtag
respiratori
viral
panel
luminex
corpor
austin
tx
daili
throughput
patient
sampl
may
severalfold
greater
tac
assay
instrument
cost
may
greater
well
clinic
laboratori
move
toward
implement
array
technolog
interassay
compar
data
would
inform
major
strength
studi
use
larg
collect
field
specimen
wellcharacter
group
children
enrol
nvsn
fulli
examin
clinic
perform
tac
assay
realworld
clinic
diagnost
laboratori
set
individu
rtqpcr
optim
maximum
sensit
gold
standard
rich
nvsn
epidemiolog
clinic
databas
combin
tac
assay
result
permit
evalu
clinic
relev
codetect
two
pediatr
respiratori
pathogen
includ
commonli
studi
eg
influenza
c
human
coronavirus
new
pathogen
becom
recogn
rtqpcr
assay
becom
avail
quickli
easili
introduc
tac
array
use
investig
outbreak
respiratori
ill
unknown
etiolog
fund
support
part
cooper
agreement
center
diseas
control
prevent
